New research raises troubling concerns about the use of aggressive drug therapies to treat a wide range of diseases such as infections from MRSA, C. difficile and malaria, and even cancer.
"The universally accepted strategy of aggressive medication to kill all targeted disease pathogens has the problematic consequence of giving any drug-resistant disease pathogens that are present the greatest possible evolutionary advantage," says Troy Day, one of the papers co-authors and Canada Research Chair in Mathematical Biology at Queens University.
The researchers note that while the first aim of a drug treatment program should be to make and keep a patient healthy, the patients immune system also has to be allowed to work.
They suggest several strategies to address the challenge of drug-resistant pathogens including improving the current knowledge base, discovering effective ways for slowing the spread of drug-resistant pathogens from person-to-person, and developing strategies for preventing drug-resistant mutations from occurring in the first place.
Last centurys malaria wonder drug, chloroquine, is a perfect example of aggressive medication leading to the growth of drug-resistant pathogens. Since drug-resistant malarial parasites didnt have to compete with parasites that were killed off by an aggressive chloroquine treatment plan, the resistant parasites were given an evolutionary advantage. As a treatment for malaria, chloroquine is now useless across most of Africa.
"As things currently stand, no research exists that can tell us what the optimal drug delivery strategy would be for maintaining treatment effectiveness and mitigating the evolution of resistance," says Day. "While overwhelming medicinal force may sometimes be required, we need to be clear about when and why this strategy should be chosen since it brings with it some very clear problems with respect to resistance evolution."
This research was conducted in collaboration with Andrew Read and Silvie Huijben at Pennsylvania State University and was published in a recent issue of the Proceedings of the National Academy of Sciences.
“Ongoing Assault”: How HHS Layoffs Have Eviscerated Infection Prevention Support Across the Nation
April 1st 2025Mass layoffs at HHS and CDC have gutted critical infection prevention programs, leaving frontline professionals overwhelmed, under-resourced, and desperate to safeguard public health.
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.